Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
Cancer Reports · 2025
DOI: 10.1002/cnr2.70117 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Reports, 2025. Verfasst von DENO Research Group und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario y Politécnico La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Denosumab, Bone Neoplasms, Giant Cell Tumor of Bone, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.
Aims
To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab. Methods and Results This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients ( n = 11), with a median recurrence‐free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence‐free survival time of 9 months (5–25 months).
Conclusion
The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Hospital Clínico San Carlos, Madrid, Spain.
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
- Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain.
- Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
ORCID-Profile: Carolina de la Calva, Paula González-Rojo
Zitieren
APA
DENO Research Group, de la Calva, C., Angulo, M., González-Rojo, P., Peiró, A., Machado, P., Cebrián, J. L., García-Maroto, R., Valcárcel, A., Puertas, P., Valero-Cifuentes, G., Pablos, Ó., Maireles, M., Fontalva, M. L., Chaves, I., Orce, A., Coll-Mesa, L., Pérez, I., González, F., …, & Gracia, I. (2025). Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?. Cancer Reports. https://doi.org/10.1002/cnr2.70117
Vancouver
DENO Research Group, de la Calva C, Angulo M, González-Rojo P, Peiró A, Machado P, et al. Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?. Cancer Reports. 2025. doi:10.1002/cnr2.70117
BibTeX
@article{DENOResearchGroup2025,
author = {DENO Research Group, DENO Research Group and de la Calva, Carolina and Angulo, Manuel and González-Rojo, Paula and Peiró, Ana and Machado, Pau and Cebrián, Juan Luis and García-Maroto, Roberto and Valcárcel, Antonio and Puertas, Pablo and Valero-Cifuentes, Gregorio and Pablos, Óscar and Maireles, Miriam and Fontalva, María Luisa and Chaves, Iván and Orce, Aida and Coll-Mesa, Luis and Pérez, Israel and González, Fausto and Del Carmen Sanz, María and Gracia, Isidro},
title = {Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70117}
}
EUVIMED